Compounds > thiazoles
Page last updated: 2024-08-21

thiazoles and ribociclib

thiazoles has been researched along with ribociclib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Han, ES; Mortimer, J; Wen, W; Xing, Q; Yan, J; Yim, JH; Yost, SE; Yuan, Y1
Abdelhady, AM; Bachelot, T; Calvo, E; Fasolo, A; Forero-Torres, A; Hamilton, E; Im, YH; Lee, SC; Lu, YS; Maur, M; Nardi, L; Ruan, S; Stammberger, U; Tiedt, R; Tolaney, SM1
Balbin, A; Cresta, S; Crystal, A; Curigliano, G; De Vita, S; Duhoux, FP; He, W; Huober, J; Jhaveri, K; Ji, Y; Juric, D; Kundamal, N; Layman, RM; Sheng, Q; Takahashi, S; Terret, C; Yap, YS1

Other Studies

3 other study(ies) available for thiazoles and ribociclib

ArticleYear
Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
    Scientific reports, 2019, 05-17, Volume: 9, Issue:1

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Enzyme Inhibitors; Female; Humans; Mice; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2019
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-15, Volume: 27, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Purines; Receptors, Estrogen; Thiazoles

2021
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21

    Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Receptors, Estrogen; Thiazoles; Thiophenes

2021